Valeant Pharmaceuticals International Inc Chief Executive Michael Pearson said on Thursday that the company would focus on acquisitions with strong cash flow in high growth areas, avoiding western Europe and Japan, where big pharmaceutical companies dominate. A Valeant spokeswoman said the company would not comment on recent deal speculation, which has involved U.S. generic drugmaker Actavis Inc.
Actavis Inc., formerly Watson Pharmaceuticals, Inc. Shares of ACT remained unchanged at $104.39. In the past year, the shares have traded as low as $66.99 and as high as $99.55. On average, 1110020 shares of ACT exchange hands on a given day and today's volume is recorded at 0.
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX remained unchanged at $73.69. In the past year, the shares have traded as low as $42.47 and as high as $76.56. On average, 1324560 shares of VRX exchange hands on a given day and today's volume is recorded at 0.
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX fell by 2.9% or $-2.22/share to $74.28. In the past year, the shares have traded as low as $43.99 and as high as $77.70. On average, 438706 shares of VRX.TO exchange hands on a given day and today's volume is recorded at 0.
Source
